Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Prospective Imaging Trial Assessing Gadoteridol Retention in the Deep Brain Nuclei of Women Undergoing Breast MRI.

Neal CH, Pujara AC, Srinivasan A, Chenevert TL, Malyarenko D, Khalatbari S, Helvie MA, Noroozian M, Jeruss JS, Pearlman MD, Davenport MS.

Acad Radiol. 2020 Feb 24. pii: S1076-6332(20)30034-9. doi: 10.1016/j.acra.2020.01.007. [Epub ahead of print]

PMID:
32107123
2.

Precision health for breast cancer metastasis: biomaterial scaffolds as an engineered metastatic niche to define, study, and monitor metastatic progression.

Bushnell GG, Wicha MS, Jeruss JS, Lonnie D S.

Oncoscience. 2019 Dec 23;6(11-12):380-382. doi: 10.18632/oncoscience.493. eCollection 2019 Nov.

3.

Metastatic Conditioning of Myeloid Cells at a Subcutaneous Synthetic Niche Reflects Disease Progression and Predicts Therapeutic Outcomes.

Oakes RS, Bushnell GG, Orbach SM, Kandagatla P, Zhang Y, Morris AH, Hall MS, LaFaire P, Decker JT, Hartfield RM, Brooks MD, Wicha MS, Jeruss JS, Shea LD.

Cancer Res. 2020 Feb 1;80(3):602-612. doi: 10.1158/0008-5472.CAN-19-1932. Epub 2019 Oct 29.

PMID:
31662327
4.

High Frequency Spectral Ultrasound Imaging to Detect Metastasis in Implanted Biomaterial Scaffolds.

Bushnell GG, Hong X, Hartfield RM, Zhang Y, Oakes RS, Rao SS, Jeruss JS, Stegemann JP, Deng CX, Shea LD.

Ann Biomed Eng. 2020 Jan;48(1):477-489. doi: 10.1007/s10439-019-02366-2. Epub 2019 Sep 23.

PMID:
31549327
5.

Microporous scaffolds loaded with immunomodulatory lentivirus to study the contribution of immune cell populations to tumor cell recruitment in vivo.

Bushnell GG, Rao SS, Hartfield RM, Zhang Y, Oakes RS, Jeruss JS, Shea LD.

Biotechnol Bioeng. 2020 Jan;117(1):210-222. doi: 10.1002/bit.27179. Epub 2019 Oct 3.

6.

Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer.

Kandagatla P, Rizk NN, Dokic D, Kochkodan J, Estevez S, Yanik M, Goranta S, Huber-Keener K, Jeruss JS.

Breast J. 2019 Sep 20. doi: 10.1111/tbj.13528. [Epub ahead of print]

PMID:
31538708
7.

Axillary Pathologic Complete Response in Inflammatory Breast Cancer Patients: Implications for SLNB?

Imeokparia FO, Hughes TM, Dossett LA, Jeruss JS, Chang AE, Sabel MS.

Ann Surg Oncol. 2019 Oct;26(10):3374-3379. doi: 10.1245/s10434-019-07597-0. Epub 2019 Jul 24.

PMID:
31342381
8.

ASO Author Reflections: Challenges in the Management of Young Women with Breast Cancer-Fertility Preservation and Pregnancy.

Kandagatla P, Shah NM, Jeruss JS.

Ann Surg Oncol. 2019 May;26(5):1225-1226. doi: 10.1245/s10434-019-07285-z. Epub 2019 Mar 11. No abstract available.

PMID:
30859353
9.

Biomaterial Scaffolds Recruit an Aggressive Population of Metastatic Tumor Cells In Vivo.

Bushnell GG, Hardas TP, Hartfield RM, Zhang Y, Oakes RS, Ronquist S, Chen H, Rajapakse I, Wicha MS, Jeruss JS, Shea LD.

Cancer Res. 2019 Apr 15;79(8):2042-2053. doi: 10.1158/0008-5472.CAN-18-2502. Epub 2019 Feb 26.

PMID:
30808673
10.

Young Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer.

Shah NM, Scott DM, Kandagatla P, Moravek MB, Cobain EF, Burness ML, Jeruss JS.

Ann Surg Oncol. 2019 May;26(5):1214-1224. doi: 10.1245/s10434-019-07156-7. Epub 2019 Jan 24.

PMID:
30680478
11.

The National Physicians Cooperative: transforming fertility management in the cancer setting and beyond.

Smith BM, Duncan FE, Ataman L, Smith K, Quinn GP, Chang RJ, Finlayson C, Orwig K, Valli-Pulaski H, Moravek MB, Zelinski MB, Irene Su H, Vitek W, Smith JF, Jeruss JS, Gracia C, Coutifaris C, Shah D, Nahata L, Gomez-Lobo V, Appiah LC, Brannigan RE, Gillis V, Gradishar W, Javed A, Rhoton-Vlasak AS, Kondapalli LA, Neuber E, Ginsberg JP, Muller CH, Hirshfeld-Cytron J, Kutteh WH, Lindheim SR, Cherven B, Meacham LR, Rao P, Torno L, Sender LS, Vadaparampil ST, Skiles JL, Schafer-Kalkhoff T, Frias OJ, Byrne J, Westphal LM, Schust DJ, Klosky JL, McCracken KA, Ting A, Khan Z, Granberg C, Lockart B, Scoccia B, Laronda MM, Mersereau JE, Marsh C, Pavone ME, Woodruff TK.

Future Oncol. 2018 Dec;14(29):3059-3072. doi: 10.2217/fon-2018-0278. Epub 2018 Nov 26.

12.

Design of Large-Scale Reporter Construct Arrays for Dynamic, Live Cell Systems Biology.

Decker JT, Hall MS, Peñalver-Bernabé B, Blaisdell RB, Liebman LN, Jeruss JS, Shea LD.

ACS Synth Biol. 2018 Sep 21;7(9):2063-2073. doi: 10.1021/acssynbio.8b00236. Epub 2018 Sep 10.

PMID:
30189139
13.

Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2+ breast cancer.

Decker JT, Hall MS, Blaisdell RB, Schwark K, Jeruss JS, Shea LD.

Biotechnol Bioeng. 2018 Oct;115(10):2613-2623. doi: 10.1002/bit.26791. Epub 2018 Aug 2.

14.

Retrievable hydrogels for ovarian follicle transplantation and oocyte collection.

Rios PD, Kniazeva E, Lee HC, Xiao S, Oakes RS, Saito E, Jeruss JS, Shikanov A, Woodruff TK, Shea LD.

Biotechnol Bioeng. 2018 Aug;115(8):2075-2086. doi: 10.1002/bit.26721. Epub 2018 May 14.

15.

Biomaterial Scaffolds as Pre-metastatic Niche Mimics Systemically Alter the Primary Tumor and Tumor Microenvironment.

Aguado BA, Hartfield RM, Bushnell GG, Decker JT, Azarin SM, Nanavati D, Schipma MJ, Rao SS, Oakes RS, Zhang Y, Jeruss JS, Shea LD.

Adv Healthc Mater. 2018 May;7(10):e1700903. doi: 10.1002/adhm.201700903. Epub 2018 Mar 9.

16.

Strategies to Maintain Fertility in Young Breast Cancer Patients.

Constance ES, Moravek MB, Jeruss JS.

Cancer Treat Res. 2018;173:1-13. doi: 10.1007/978-3-319-70197-4_1. Review.

PMID:
29349754
17.

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.

Rao SS, Stoehr J, Dokic D, Wan L, Decker JT, Konopka K, Thomas AL, Wu J, Kaklamani VG, Shea LD, Jeruss JS.

Oncotarget. 2017 Aug 10;8(48):83925-83939. doi: 10.18632/oncotarget.20202. eCollection 2017 Oct 13.

18.

Molecular Subtypes and Local-Regional Control of Breast Cancer.

Fragomeni SM, Sciallis A, Jeruss JS.

Surg Oncol Clin N Am. 2018 Jan;27(1):95-120. doi: 10.1016/j.soc.2017.08.005. Review.

19.

Embryonic stem cell secreted factors decrease invasiveness of triple-negative breast cancer cells through regulome modulation.

Tarasewicz E, Oakes RS, Aviles MO, Straehla J, Chilton KM, Decker JT, Wu J, Shea LD, Jeruss JS.

Cancer Biol Ther. 2018 Apr 3;19(4):271-281. doi: 10.1080/15384047.2017.1385681. Epub 2018 Mar 13.

20.

New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery.

Lee JS, Hu HM, Edelman AL, Brummett CM, Englesbe MJ, Waljee JF, Smerage JB, Griggs JJ, Nathan H, Jeruss JS, Dossett LA.

J Clin Oncol. 2017 Dec 20;35(36):4042-4049. doi: 10.1200/JCO.2017.74.1363. Epub 2017 Oct 19.

21.

Engineering the pre-metastatic niche.

Aguado BA, Bushnell GG, Rao SS, Jeruss JS, Shea LD.

Nat Biomed Eng. 2017;1. pii: 0077. doi: 10.1038/s41551-017-0077. Epub 2017 Jun 13.

22.

Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.

Thomas AL, Lind H, Hong A, Dokic D, Oppat K, Rosenthal E, Guo A, Thomas A, Hamden R, Jeruss JS.

Cell Cycle. 2017 Aug 3;16(15):1453-1464. doi: 10.1080/15384101.2017.1338988. Epub 2017 Jul 5.

23.

Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells.

Decker JT, Hobson EC, Zhang Y, Shin S, Thomas AL, Jeruss JS, Arnold KB, Shea LD.

Biotechnol Bioeng. 2017 Sep;114(9):2085-2095. doi: 10.1002/bit.26293. Epub 2017 May 18.

24.

Oncofertility program implementation increases access to fertility preservation options and assisted reproductive procedures for breast cancer patients.

Vu JV, Llarena NC, Estevez SL, Moravek MB, Jeruss JS.

J Surg Oncol. 2017 Feb;115(2):116-121. doi: 10.1002/jso.24418. Epub 2016 Dec 14.

25.

Enhanced Survival with Implantable Scaffolds That Capture Metastatic Breast Cancer Cells In Vivo.

Rao SS, Bushnell GG, Azarin SM, Spicer G, Aguado BA, Stoehr JR, Jiang EJ, Backman V, Shea LD, Jeruss JS.

Cancer Res. 2016 Sep 15;76(18):5209-18. doi: 10.1158/0008-5472.CAN-15-2106.

26.

Primordial Follicle Transplantation within Designer Biomaterial Grafts Produce Live Births in a Mouse Infertility Model.

Kniazeva E, Hardy AN, Boukaidi SA, Woodruff TK, Jeruss JS, Shea LD.

Sci Rep. 2015 Dec 3;5:17709. doi: 10.1038/srep17709.

27.

In vivo capture and label-free detection of early metastatic cells.

Azarin SM, Yi J, Gower RM, Aguado BA, Sullivan ME, Goodman AG, Jiang EJ, Rao SS, Ren Y, Tucker SL, Backman V, Jeruss JS, Shea LD.

Nat Commun. 2015 Sep 8;6:8094. doi: 10.1038/ncomms9094.

28.

Impact of Fertility Concerns on Tamoxifen Initiation and Persistence.

Llarena NC, Estevez SL, Tucker SL, Jeruss JS.

J Natl Cancer Inst. 2015 Aug 25;107(10). doi: 10.1093/jnci/djv202. Print 2015 Oct.

29.

Understanding Fertility in Young Female Cancer Patients.

Waimey KE, Smith BM, Confino R, Jeruss JS, Pavone ME.

J Womens Health (Larchmt). 2015 Oct;24(10):812-8. doi: 10.1089/jwh.2015.5194. Epub 2015 Jun 15. Review.

30.

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).

Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W.

Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26.

PMID:
26006067
31.

Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.

Tarasewicz E, Rivas L, Hamdan R, Dokic D, Parimi V, Bernabe BP, Thomas A, Shea LD, Jeruss JS.

Cell Cycle. 2014;13(20):3191-201. doi: 10.4161/15384101.2014.950126.

32.

Dynamic transcription factor activity and networks during ErbB2 breast oncogenesis and targeted therapy.

Weiss MS, Peñalver Bernabé B, Shin S, Asztalos S, Dubbury SJ, Mui MD, Bellis AD, Bluver D, Tonetti DA, Saez-Rodriguez J, Broadbelt LJ, Jeruss JS, Shea LD.

Integr Biol (Camb). 2014 Dec;6(12):1170-82. doi: 10.1039/c4ib00086b.

33.

A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.

Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan ME, Margenthaler JA, Chatterton RT Jr, Jovanovic B, Dunn BK, Heckman-Stoddard BM, Foster K, Muzzio M, Shklovskaya J, Skripkauskas S, Kulesza P, Green D, Hansen NM, Bethke KP, Jeruss JS, Bergan R, Khan SA.

Clin Cancer Res. 2014 Jul 15;20(14):3672-82. doi: 10.1158/1078-0432.CCR-13-3045.

34.

CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.

Tarasewicz E, Hamdan R, Straehla J, Hardy A, Nunez O, Zelivianski S, Dokic D, Jeruss JS.

Cancer Biol Ther. 2014 Oct;15(10):1301-11. doi: 10.4161/cbt.29693. Epub 2014 Jul 9.

35.

Risk factors for unplanned readmissions following excisional breast surgery.

Khavanin N, Bethke KP, Lovecchio FC, Jeruss JS, Hansen NM, Kim JY.

Breast J. 2014 May-Jun;20(3):288-94. doi: 10.1111/tbj.12253. Epub 2014 Apr 2.

PMID:
24689860
36.

Abstract 46: The BRA Score: Creating a General Risk Calculator for Breast Reconstruction Outcomes.

Khavanin N, Kim JY, Davila AA, Ver Halen JP, Mlodinow AS, Bethke KP, Khan SA, Jeruss JS, Hansen NM, Bilimoria KY, Losken A, Fine NA.

Plast Reconstr Surg. 2014 Mar;133(3 Suppl):56-7. doi: 10.1097/01.prs.0000445079.93837.65. No abstract available.

PMID:
25942157
37.

Tumescent technique does not increase the risk of complication following mastectomy with immediate reconstruction.

Khavanin N, Fine NA, Bethke KP, Mlodinow AS, Khan SA, Jeruss JS, Hansen NM, Kim JY.

Ann Surg Oncol. 2014 Feb;21(2):384-8. doi: 10.1245/s10434-013-3311-0. Epub 2013 Oct 12.

PMID:
24121881
38.

Dynamic transcription factor networks in epithelial-mesenchymal transition in breast cancer models.

Siletz A, Schnabel M, Kniazeva E, Schumacher AJ, Shin S, Jeruss JS, Shea LD.

PLoS One. 2013 Apr 8;8(4):e57180. doi: 10.1371/journal.pone.0057180. Print 2013.

39.

Lives in the balance: women with cancer and the right to fertility care.

Gracia CR, Jeruss JS.

J Clin Oncol. 2013 Feb 20;31(6):668-9. doi: 10.1200/JCO.2012.47.5798. Epub 2013 Jan 22. No abstract available.

40.

Transcription factor networks in invasion-promoting breast carcinoma-associated fibroblasts.

Siletz A, Kniazeva E, Jeruss JS, Shea LD.

Cancer Microenviron. 2013 Apr;6(1):91-107. doi: 10.1007/s12307-012-0121-z. Epub 2012 Oct 23.

41.

A mother and daughter with phyllodes tumors of the breast.

Foucar CE, Hardy A, Siziopikou KP, Wang L, Parini V, Hansen N, Jeruss JS.

Clin Breast Cancer. 2012 Oct;12(5):373-7. doi: 10.1016/j.clbc.2012.07.011. Epub 2012 Sep 14. No abstract available.

PMID:
22981939
42.

Phospho-specific Smad3 signaling: impact on breast oncogenesis.

Tarasewicz E, Jeruss JS.

Cell Cycle. 2012 Jul 1;11(13):2443-51. doi: 10.4161/cc.20546. Epub 2012 Jul 1. Review.

43.

Impact of infertility regimens on breast cancer cells: follicle-stimulating hormone and luteinizing hormone lack a direct effect on breast cell proliferation in vitro.

Boukaidi SA, Cooley A, Hardy A, Matthews L, Zelivianski S, Jeruss JS.

Fertil Steril. 2012 Feb;97(2):440-4. doi: 10.1016/j.fertnstert.2011.11.020. Epub 2011 Dec 19.

44.

Effect of infertility treatment and pregnancy-related hormones on breast cell proliferation in vitro.

Cooley A, Matthews L, Zelivianski S, Hardy A, Jeruss JS.

Hum Reprod. 2012 Jan;27(1):146-52. doi: 10.1093/humrep/der378. Epub 2011 Nov 10.

45.

Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.

Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK.

J Clin Oncol. 2011 May 20;29(15):1956-62. doi: 10.1200/JCO.2010.31.8469. Epub 2011 Apr 11.

46.

Fertility preservation options for young women with breast cancer.

Hulvat MC, Jeruss JS.

Curr Opin Obstet Gynecol. 2011 Jun;23(3):174-82. doi: 10.1097/GCO.0b013e328345525a. Review.

PMID:
21415746
47.

Ductal carcinoma in situ treated with breast-conserving surgery and accelerated partial breast irradiation: comparison of the Mammosite registry trial with intergroup study E5194.

Goyal S, Vicini F, Beitsch PD, Kuerer H, Keisch M, Motwani S, Jeruss JS, Lyden M, Haffty BG.

Cancer. 2011 Mar 15;117(6):1149-55. doi: 10.1002/cncr.25615. Epub 2010 Nov 2.

48.

Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.

Kaklamani VG, Siziopikou K, Scholtens D, Lacouture M, Gordon J, Uthe R, Meservey C, Hansen N, Khan SA, Jeruss JS, Bethke K, Cianfrocca M, Rosen S, Von Roenn J, Wayne J, Parimi V, Jovanovic B, Gradishar W.

Breast Cancer Res Treat. 2012 Apr;132(3):833-42. doi: 10.1007/s10549-011-1411-8. Epub 2011 Feb 27.

PMID:
21359953
49.

Incorporating fertility preservation into the care of young oncology patients.

Redig AJ, Brannigan R, Stryker SJ, Woodruff TK, Jeruss JS.

Cancer. 2011 Jan 1;117(1):4-10.

50.

Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines.

Cooley A, Zelivianski S, Jeruss JS.

Cell Cycle. 2010 Dec 15;9(24):4900-7. Epub 2010 Dec 15.

Supplemental Content

Loading ...
Support Center